A L Lukyanov

City Clinical Hospital No. 31 named after Academician G.M. Savelyeva, Moscow, Russia.

1 publication 2025 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does A L Lukyanov research?

A L Lukyanov studies how to treat ischemic strokes (a type of stroke caused by blocked blood flow to the brain) using a medication called Revelise (alteplase). His research emphasizes the real-world application of this treatment, particularly observing how well it performs in older patients and those with other health complications. By monitoring patient outcomes, he aims to improve recovery and reduce disabilities associated with strokes.

Key findings

  • In a study of 2,202 patients, nearly half (49.9%) experienced good outcomes at discharge after receiving Revelise.
  • After 90 days, the percentage of patients with good outcomes increased to 66.4%.
  • Revelise effectively reduces stroke-related disabilities, even in older patients and those with existing health issues.

Frequently asked questions

Does Dr Lukyanov study ischemic stroke?
Yes, Dr Lukyanov specifically focuses on ischemic stroke and its treatment using Revelise.
What treatments has Dr Lukyanov researched?
He has researched thrombolytic therapy using the medication Revelise for treating ischemic stroke.
Is Dr Lukyanov's work relevant to older stroke patients?
Yes, his research shows that Revelise is effective and safe for older patients, improving their recovery outcomes.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.